Hosted by Drug Discovery World and supported by Bio-Techne, this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
This eBook explores the latest developments in artificial intelligence (AI), computational models and quantum computing that are driving drug discovery today.
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader (MGD), was shown to normalise multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. Monte Rosa Therapeutics announced the finding along with other positive data from GFORCE-1, a Phase I study evaluating MRT-8102, which… Read More
A new eBook titled ‘Accelerating drug discovery with rational design’ is now available exclusively to DDW readers from Thermo Fisher Scientific. The eBook explores real-world examples demonstrating how high-resolution structural insights can inform earlier decisions, illuminate mechanisms of action, and help reduce the time, cost, and risk associated with advancing… Read More
Numab Therapeutics has appointed Dr Rajesh Chopra as Chief Scientific Officer, who brings nearly four decades of experience across oncology, immunology, translational medicine, and drug development. Dr Chopra joined Numab from Prologue Medicines, where he served as Chief Scientific Officer, and previously was a Venture Partner at… Read More
Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More
Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate. The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More
Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze… Read More
The US Food and Drug Administration (FDA) has given the go-ahead to Genentech’s Gazyva (obinutuzumab) in adult and paediatric patients two years of age and older. It is approved to reduce the risk of relapse in patients with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome… Read More
Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research. His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More
Scarlet Therapeutics has entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to advance the development of smart red blood cells (SRBCs). Scarlet will lead a multidisciplinary consortium to develop SRBCs in a programme worth up to $14 million. The agreement builds… Read More
An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines. They argue that Europe is losing ground to global competition, with over $600 billion in… Read More
A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases. The collaboration includes development of long-acting injectable formulations with different administration-frequency… Read More
Skylark Bio has revealed it is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS). SKY-AS represents the company’s first central nervous system (CNS) development programme and expands Skylark’s portfolio of precision, locally delivered… Read More
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients. It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is… Read More
Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers. The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More
